Harvard Tissue Atlas Harvard Medical School
Data
Back to Atlases main

BRCA1/2 Cancer Atlas

The mutations that cause cancer often arise spontaneously in somatic tissues but some are heritable. Among these mutations in BRCA1 or BRCA2 (BReast CAncer gene 1&2) stand out as having relatively high prevalence and causing a substantial increase in a variety of cancers including those of the breast, ovaries, pancreas and prostate. BRCA1 and BRCA2 are involved in the repair of damaged DNA but the precise events that initiate tumor formation are not fully understood.

Principal Investigators

  • Joan Brugge, PhD, Director of the Harvard Ludwig Cancer Center and Professor of Cell Biology, Harvard Medical School
  • Sandro Santagata, MD PhD, Associate Professor of Pathology, Brigham and Women’s Hospital and Harvard Medical School
  • Peter Sorger, PhD, Professor of Systems Biology, Harvard Medical School

Publications

A human breast atlas integrating single-cell proteomics and transcriptomics.

A human breast atlas integrating single-cell proteomics and transcriptomics.

Gray, G.K., Li, C.M.-C., Rosenbluth, J.M., Selfors, L.M., Girnius, N., Lin, J.-R., Schackmann, R.C.J., Goh, W.L., Moore, K., Shapiro, H.K., Mei, S., D’Andrea, K., Nathanson, K.L., Sorger, P.K., Santagata, S., Regev, A., Garber, J.E., Dillon, D.A., Brugge, J.S. (2022).
Developmental Cell, 57(22), 1400-1420. https://doi.org/10.1016/j.devcel.2022.05.003
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.

Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.

Mehta, A.K., Cheney, E.M., Hartl, C.A., Pantelidou, C., Oliwa, M., Castrillon, J.A., Lin, Lin, J.-R., ... Guerriero, J. (2021).
Nature Cancer, 2(1), 66–82. https://doi.org/10.1038/s43018-020-00148-7
Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer.

Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer.

Keenan, T.E., Li, T., Vallius, T., Guerriero, J.L., Tayob, N., Kochupurakkal, B., Davis, J., Pastorello, R., ... Tolaney, S.M. (2021).
Clinical Cancer Research, 2(1), 66-82. https://doi.org/10.1158/1078-0432.CCR-20-3089

Data Explorations

Data Explorations are like museum guides and exploit the digital docents in MINERVA to guide readers through the complexities of a large image dataset via a series of narrated stories and waypoints.

Data image
BRCA WT vs BRCA1 associated TNBC

Data Overviews

Data Overviews provide access to minimally processed Level 2 images with no annotation or quality control. Click any of the following thumbnail images for an interactive view of the full-resolution images.

Data image
jenntnbc4m33118
Data image
BRCA1-associated-9
Data image
BRCA1-associated-8
Data image
BRCA1-associated-7
Data image
BRCA1-associated-6
Data image
BRCA1-associated-5
Data image
BRCA1-associated-4
Data image
BRCA1-associated-3
Data image
BRCA1-associated-2
Data image
BRCA1-associated-10
Data image
BRCA1-associated-1
Data image
BRCA WT vs BRCA1 associated TNBC
Data image
BRCA-WT-6
Data image
BRCA-WT-5
Data image
BRCA-WT-4
Data image
BRCA-WT-3
Data image
BRCA-WT-2
Data image
BRCA-WT-1
Data image
Clinical Benefit - Cisplatin Biopsy
Data image
Clinical Benefit - Cis Wee1i Biopsy
Data image
No Clinical Benefit - Cis Wee1i Biopsy
Data image
No Clinical Benefit - Cisplatin Biopsy

Funding

This research is funded by the Gray Foundation Basser Initiative, the Ludwig Institute for Cancer Research, and the National Cancer Institute (NCI U54 CA225088).